Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea
Sponsor: University of Cincinnati
Summary
Irritable bowel syndrome is a functional disorder of the gastrointestinal tract diagnosed with the Rome criteria. The Rome IV criteria are based on abdominal pain symptoms and stool habits including stool frequency and stool forms \[1\]. They define 3 main subtypes based on symptoms: 1) IBS with diarrhea; 2) IBS with constipation: and 3) mixed symptoms of constipation and diarrhea. The IBS with diarrhea (IBS-D) subtype has the highest prevalence. Currently, treatment of IBS-D includes antidiarrheals, bile acid sequestrants, antispasmodics, tricyclic antidepressants, and FODMAP diet. However, many patients are intolerant or unresponsive to the above treatments. Outside of IBS, chronic diarrhea affects about 5% of adults. We have described a syndrome in a subset of IBS patients presenting with post prandial diarrhea, flushing and dermatographia whose symptoms are prevented by pre-treatment with combined H1 and H2 antihistamines \[2\]. However, the prevalence of this syndrome among the IBS + D patients is not known nor have the clinical characteristics or predictors of antihistamine responsive IBS + D been defined.
Official title: Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea: a Cross-Over Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2020-02-01
Completion Date
2026-08-31
Last Updated
2026-09-04
Healthy Volunteers
No
Interventions
Antihistamine
Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
Placebo
These medications will be pre-packaged by the UC Health pharmacy in a manner that results in a double-blinded cross-over design.
Locations (1)
UC Health
Cincinnati, Ohio, United States